Welireg® (belzutifan) – New indication
May 14, 2025 - Merck announced the FDA approval of Welireg (belzutifan), for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
Download PDF
